These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 36773034)

  • 1. Ipatasertib, an oral AKT inhibitor, in combination with carboplatin exhibits anti-proliferative effects in uterine serous carcinoma.
    Burkett WC; Zhao Z; Newton MA; Sun W; Deng B; Secord AA; Zhou C; Bae-Jump V
    Ann Med; 2023 Dec; 55(1):603-614. PubMed ID: 36773034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ipatasertib, an oral AKT inhibitor, inhibits cell proliferation and migration, and induces apoptosis in serous endometrial cancer.
    Buckingham L; Hao T; O'Donnell J; Zhao Z; Zhang X; Fan Y; Sun W; Zhang Y; Suo H; Secord AA; Zhou C; Bae-Jump V
    Am J Cancer Res; 2022; 12(6):2850-2862. PubMed ID: 35812065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose ascorbate exerts anti-tumor activities and improves inhibitory effect of carboplatin through the pro-oxidant function pathway in uterine serous carcinoma cell lines.
    Shen X; Wang J; Deng B; Chen S; John C; Zhao Z; Sinha N; Haag J; Sun W; Kong W; Spasojevic I; Batinic-Haberle I; Secord AA; Zhou C; Bae-Jump VL
    Gynecol Oncol; 2024 Apr; 183():93-102. PubMed ID: 38555710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ridaforolimus improves the anti-tumor activity of dual HER2 blockade in uterine serous carcinoma in vivo models with HER2 gene amplification and PIK3CA mutation.
    Hernandez SF; Chisholm S; Borger D; Foster R; Rueda BR; Growdon WB
    Gynecol Oncol; 2016 Jun; 141(3):570-579. PubMed ID: 27017985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ipatasertib exhibits anti‑tumorigenic effects and enhances sensitivity to paclitaxel in endometrial cancer
    O'Donnell J; Zhao Z; Buckingham L; Hao T; Suo H; Zhang X; Fan Y; John C; Deng B; Shen X; Sun W; Secord AA; Zhou C; Bae-Jump VL
    Int J Oncol; 2023 Sep; 63(3):. PubMed ID: 37503790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of Mtorc1/2 and DNA-PK via CC-115 Synergizes with Carboplatin and Paclitaxel in Lung Squamous Cell Carcinoma.
    Castellano GM; Zeeshan S; Garbuzenko OB; Sabaawy HE; Malhotra J; Minko T; Pine SR
    Mol Cancer Ther; 2022 Sep; 21(9):1381-1392. PubMed ID: 35732569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular alterations of EGFR and PIK3CA in uterine serous carcinoma.
    Hayes MP; Douglas W; Ellenson LH
    Gynecol Oncol; 2009 Jun; 113(3):370-3. PubMed ID: 19272638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncogenic PIK3CA gene mutations and HER2/neu gene amplifications determine the sensitivity of uterine serous carcinoma cell lines to GDC-0980, a selective inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2).
    English DP; Bellone S; Cocco E; Bortolomai I; Pecorelli S; Lopez S; Silasi DA; Schwartz PE; Rutherford T; Santin AD
    Am J Obstet Gynecol; 2013 Nov; 209(5):465.e1-9. PubMed ID: 23891627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Doubling down on the PI3K-AKT-mTOR pathway enhances the antitumor efficacy of PARP inhibitor in triple negative breast cancer model beyond BRCA-ness.
    De P; Sun Y; Carlson JH; Friedman LS; Leyland-Jones BR; Dey N
    Neoplasia; 2014 Jan; 16(1):43-72. PubMed ID: 24563619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines In Vitro and In Vivo.
    Lopez S; Cocco E; Black J; Bellone S; Bonazzoli E; Predolini F; Ferrari F; Schwab CL; English DP; Ratner E; Silasi DA; Azodi M; Schwartz PE; Terranova C; Angioli R; Santin AD
    Mol Cancer Ther; 2015 Nov; 14(11):2519-26. PubMed ID: 26333383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sulindac exhibits anti-proliferative and anti-invasive effects in uterine serous carcinoma cells.
    Chen S; Kong W; Shen X; Deng B; Haag J; Sinha N; John C; Sun W; Zhou C; Bae-Jump VL
    J Cancer Res Clin Oncol; 2024 Aug; 150(8):402. PubMed ID: 39198302
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early stage uterine serous carcinoma: management updates and genomic advances.
    Fader AN; Santin AD; Gehrig PA
    Gynecol Oncol; 2013 Apr; 129(1):244-50. PubMed ID: 23321062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted therapy in uterine serous carcinoma: an aggressive variant of endometrial cancer.
    Black JD; English DP; Roque DM; Santin AD
    Womens Health (Lond); 2014 Jan; 10(1):45-57. PubMed ID: 24328598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effectiveness of Carboplatin plus Taxane Chemotherapy for Advanced or Recurrent Uterine Serous Carcinoma].
    Matsuura T; Otsuka I
    Gan To Kagaku Ryoho; 2016 Nov; 43(11):1401-1404. PubMed ID: 27899784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autophagy inhibitor potentiates the antitumor efficacy of apatinib in uterine sarcoma by stimulating PI3K/Akt/mTOR pathway.
    Chen S; Yao L
    Cancer Chemother Pharmacol; 2021 Aug; 88(2):323-334. PubMed ID: 33978839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessing the efficacy of targeting the phosphatidylinositol 3-kinase/AKT/mTOR signaling pathway in endometrial cancer.
    Bradford LS; Rauh-Hain A; Clark RM; Groeneweg JW; Zhang L; Borger D; Zukerberg LR; Growdon WB; Foster R; Rueda BR
    Gynecol Oncol; 2014 May; 133(2):346-52. PubMed ID: 24561032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ryanodine receptor 1-mediated Ca
    Zhang L; Au-Yeung CL; Huang C; Yeung TL; Ferri-Borgogno S; Lawson BC; Kwan SY; Yin Z; Wong ST; Thomas V; Lu KH; Yip KP; Sham JSK; Mok SC
    J Exp Clin Cancer Res; 2022 Aug; 41(1):242. PubMed ID: 35953818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of gamma-secretase activity impedes uterine serous carcinoma growth in a human xenograft model.
    Groeneweg JW; Hall TR; Zhang L; Kim M; Byron VF; Tambouret R; Sathayanrayanan S; Foster R; Rueda BR; Growdon WB
    Gynecol Oncol; 2014 Jun; 133(3):607-15. PubMed ID: 24667249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual CCNE1/PIK3CA targeting is synergistic in CCNE1-amplified/PIK3CA-mutated uterine serous carcinomas in vitro and in vivo.
    Cocco E; Lopez S; Black J; Bellone S; Bonazzoli E; Predolini F; Ferrari F; Schwab CL; Menderes G; Zammataro L; Buza N; Hui P; Wong S; Zhao S; Bai Y; Rimm DL; Ratner E; Litkouhi B; Silasi DA; Azodi M; Schwartz PE; Santin AD
    Br J Cancer; 2016 Jul; 115(3):303-11. PubMed ID: 27351214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phosphorylation of STAT1 serine 727 enhances platinum resistance in uterine serous carcinoma.
    Zeng X; Baba T; Hamanishi J; Matsumura N; Kharma B; Mise Y; Abiko K; Yamaguchi K; Horikawa N; Hunstman DG; Mulati K; Kitamura S; Taki M; Murakami R; Hosoe Y; Mandai M
    Int J Cancer; 2019 Sep; 145(6):1635-1647. PubMed ID: 31228268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.